^
    Back
    Association details:
    Biomarker:KRAS G12V
    Cancer:Non Small Cell Lung Cancer
    Drug:Koselugo (selumetinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Br J Cancer
    Title:

    Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

    Excerpt:
    In patients receiving selumetinib+docetaxel and harbouring KRAS G12C or G12V mutations there were trends towards greater improvement in OS, PFS and ORR compared with other KRAS mutations.
    Secondary therapy:
    docetaxel
    DOI:
    10.1038/bjc.2015.215